Search research articles
Contact Us
Filters
Showing results (71-80 of 77) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 77 results.
Allergy
|
February 4, 2021
EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis
Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, et al.
Allergy
|
July 29, 2021
EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old
Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, et al.
BMJ Open
|
July 11, 2025
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
Matthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, et al.
Allergy
|
July 22, 2020
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
Ioana Agache, Yang Song, Margarita Posso, et al.
Allergy
|
August 9, 2020
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines
Ioana Agache, Claudio Rocha, Ana Pereira, et al.
Nature Communications
|
November 26, 2024
Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
Dimitrii Pogorelov, Sebastian Felix Nepomuk Bode, Xin He, et al.
Allergy
|
August 5, 2024
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration
Claudia Traidl-Hoffmann, Jamie Afghani, Cezmi A Akdis, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 77) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 77 results.
Allergy
|
February 4, 2021
EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis
Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, et al.
Allergy
|
July 29, 2021
EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old
Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, et al.
BMJ Open
|
July 11, 2025
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
Matthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, et al.
Allergy
|
July 22, 2020
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
Ioana Agache, Yang Song, Margarita Posso, et al.
Allergy
|
August 9, 2020
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines
Ioana Agache, Claudio Rocha, Ana Pereira, et al.
Nature Communications
|
November 26, 2024
Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
Dimitrii Pogorelov, Sebastian Felix Nepomuk Bode, Xin He, et al.
Allergy
|
August 5, 2024
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration
Claudia Traidl-Hoffmann, Jamie Afghani, Cezmi A Akdis, et al.
Page
of 8